Invesco Ltd. Decreases Stock Position in Option Care Health, Inc. $OPCH

Key Points

• Invesco Ltd. reduced its stake in Option Care Health, Inc. by 14.4%, owning approximately $10.02 million worth of shares as of the latest SEC filing.
• Option Care Health reported better-than-expected quarterly earnings with an EPS of $0.41, surpassing analysts' estimates of $0.40.
• Investment analysts have a consensus rating of "Moderate Buy" for Option Care Health, with an average target price set at $35.75.

Invesco Ltd. decreased its holdings in shares of Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 14.4% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 286,685 shares of the company's stock after selling 48,381 shares during the period. Invesco Ltd. owned approximately 0.18% of Option Care Health worth $10,020,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of OPCH. Compass Wealth Management LLC boosted its position in Option Care Health by 8.9% in the first quarter. Compass Wealth Management LLC now owns 166,078 shares of the company's stock valued at $5,804,000 after buying an additional 13,600 shares during the last quarter. Bessemer Group Inc. boosted its position in Option Care Health by 62.3% in the first quarter. Bessemer Group Inc. now owns 1,560 shares of the company's stock valued at $54,000 after buying an additional 599 shares during the last quarter. Principal Financial Group Inc. boosted its position in Option Care Health by 1.4% in the first quarter. Principal Financial Group Inc. now owns 485,871 shares of the company's stock valued at $16,981,000 after buying an additional 6,616 shares during the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in Option Care Health by 25.7% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 8,274 shares of the company's stock valued at $289,000 after buying an additional 1,691 shares during the last quarter. Finally, GAMMA Investing LLC boosted its position in Option Care Health by 307.1% in the first quarter. GAMMA Investing LLC now owns 3,192 shares of the company's stock valued at $112,000 after buying an additional 2,408 shares during the last quarter. Hedge funds and other institutional investors own 98.05% of the company's stock.

Insider Activity at Option Care Health

In related news, Director Harry M. Jansen Kraemer, Jr. purchased 36,000 shares of the business's stock in a transaction that occurred on Wednesday, August 20th. The stock was bought at an average price of $27.15 per share, with a total value of $977,400.00. Following the acquisition, the director owned 375,390 shares in the company, valued at $10,191,838.50. The trade was a 10.61% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Timothy P. Sullivan acquired 20,000 shares of the firm's stock in a transaction on Thursday, August 21st. The shares were bought at an average cost of $27.51 per share, for a total transaction of $550,200.00. Following the completion of the acquisition, the director owned 49,229 shares of the company's stock, valued at approximately $1,354,289.79. This represents a 68.43% increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 0.64% of the company's stock.

Option Care Health Stock Performance

Shares of NASDAQ OPCH traded down $0.07 during midday trading on Friday, reaching $28.68. 1,554,512 shares of the stock were exchanged, compared to its average volume of 1,808,057. The firm has a market cap of $4.65 billion, a price-to-earnings ratio of 22.94, a PEG ratio of 1.75 and a beta of 0.79. Option Care Health, Inc. has a twelve month low of $21.39 and a twelve month high of $35.53. The firm has a 50-day simple moving average of $29.60 and a two-hundred day simple moving average of $31.65. The company has a quick ratio of 1.00, a current ratio of 1.52 and a debt-to-equity ratio of 0.81.

Option Care Health (NASDAQ:OPCH - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The company reported $0.41 EPS for the quarter, topping analysts' consensus estimates of $0.40 by $0.01. The business had revenue of $1.42 billion for the quarter, compared to analysts' expectations of $1.35 billion. Option Care Health had a net margin of 3.93% and a return on equity of 17.53%. The business's revenue was up 15.4% on a year-over-year basis. During the same quarter last year, the company earned $0.30 EPS. Option Care Health has set its FY 2025 guidance at 1.650-1.720 EPS. As a group, analysts anticipate that Option Care Health, Inc. will post 1.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Barrington Research reiterated an "outperform" rating and issued a $38.00 target price on shares of Option Care Health in a research report on Thursday, July 10th. Citigroup reiterated an "outperform" rating on shares of Option Care Health in a research report on Thursday, July 31st. Finally, JMP Securities upped their target price on Option Care Health from $36.00 to $38.00 and gave the company a "market outperform" rating in a research report on Thursday, July 31st. Eight research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, Option Care Health currently has an average rating of "Moderate Buy" and a consensus price target of $35.75.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.